Trials / Completed
CompletedNCT02804776
PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
PROGRESS: PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- National Cancer Centre, Singapore · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This is a pharmacodynamic study to evaluate the effect of gefitinib as induction therapy for patients who have resectable, Epidermal growth factor receptor (EGFR) sensitizing mutation lung cancer.
Detailed description
Selected patients will receive 4 weeks of gefitinib before surgery. A Positron Emission Tomography - Computed Tomography (PET- CT) will be performed before and after gefitinib to assess the response. Circulating tumour cells (CTCs) and plasma Deoxyribonucleic acid (DNA) will be acquired at baseline, 2 weeks and 4 weeks after gefitinib treatment. Resected tumor will be sectored in details to study the spatial heterogeneity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefitinib | 250mg oral daily for 4 weeks |
Timeline
- Start date
- 2015-01-27
- Primary completion
- 2018-02-21
- Completion
- 2018-02-21
- First posted
- 2016-06-17
- Last updated
- 2021-06-02
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT02804776. Inclusion in this directory is not an endorsement.